GAMMA Investing LLC Has $183,000 Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

GAMMA Investing LLC increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 3,851.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,678 shares of the company's stock after acquiring an additional 6,509 shares during the quarter. GAMMA Investing LLC's holdings in Kymera Therapeutics were worth $183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of KYMR. Rhumbline Advisers boosted its holdings in shares of Kymera Therapeutics by 3.0% during the 4th quarter. Rhumbline Advisers now owns 64,157 shares of the company's stock valued at $2,581,000 after acquiring an additional 1,861 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Kymera Therapeutics by 4.5% during the 4th quarter. Bank of New York Mellon Corp now owns 127,093 shares of the company's stock valued at $5,113,000 after acquiring an additional 5,448 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Kymera Therapeutics by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock worth $15,577,000 after buying an additional 20,346 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Kymera Therapeutics by 174.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,899 shares of the company's stock worth $801,000 after buying an additional 12,643 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of Kymera Therapeutics by 15.5% in the fourth quarter. Arizona State Retirement System now owns 11,221 shares of the company's stock worth $451,000 after buying an additional 1,503 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KYMR. Stifel Nicolaus began coverage on shares of Kymera Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price objective on the stock. Guggenheim reissued a "buy" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, June 3rd. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. B. Riley raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the company from $38.00 to $60.00 in a report on Tuesday, June 3rd. Finally, UBS Group reduced their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Two analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $59.82.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR traded up $0.85 during trading hours on Tuesday, hitting $47.14. The company's stock had a trading volume of 570,077 shares, compared to its average volume of 613,052. The business's 50-day moving average is $35.46 and its two-hundred day moving average is $35.71. The company has a market capitalization of $3.07 billion, a PE ratio of -15.21 and a beta of 2.07. Kymera Therapeutics, Inc. has a 52-week low of $19.45 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million during the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The firm's quarterly revenue was up 114.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.69) EPS. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Elena Ridloff sold 12,000 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total value of $553,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the sale, the chief executive officer now owns 660,482 shares of the company's stock, valued at approximately $32,363,618. This trade represents a 4.34% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,349 shares of company stock valued at $2,334,301. Corporate insiders own 16.01% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.